Prospective validation of a composite end point in thrombolytic trials of acute myocardial infarction (TIMI 4 and 5)

American Journal of Cardiology

Volumn 80, Issue 6, 1997, Pages 696-699

  Cannon, Christopher P ^a   Sharis, Peter J ^b   Schweiger, Marc J ^b   McCabe, Carolyn H ^b   Diver, Daniel J ^b   Shan, Prediman K ^b   Sequeira, Rafael F ^b   Greene, Robert M ^b   Perritt, Rebecca L ^b   Poole, W Kenneth ^b   Braunwald, Eugene ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; HEPARIN; HIRUDIN; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ARTICLE; BLEEDING TENDENCY; BRAIN HEMORRHAGE; CARDIOGENIC SHOCK; CONGESTIVE HEART FAILURE; FIBRINOLYTIC THERAPY; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT OUTCOME; TREATMENT PLANNING;

AGED; CLINICAL TRIALS; FIBRINOLYTIC AGENTS; HEART DISEASES; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HIRUDIN THERAPY; HUMANS; MIDDLE AGED; MYOCARDIAL INFARCTION; PLASMINOGEN ACTIVATORS; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE; REPRODUCIBILITY OF RESULTS; RISK; THROMBOLYTIC THERAPY; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0031572179     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00497-9     Document Type: Article

References (27)

1. 1. Braunwald E, Cannon CP, McCabe CH. An approach to evaluating thrombolytic therapy in acute myocardial infarction. The "unsatisfactory outcome" end point. Circulation 1992;86:683-687.
2. 2. Braunwald E, Cannon CP, McCabe CH. Use of composite endpoints in thrombolysis trials of acute myocardial infarction. Am J Cardiol 1993;72:3G-12G.
3. 3. Ohman EM, Califf RM, Topol EJ, Candela R, Abbottsmith C, Ellis S, Sigmon KN, Kereiakes D, George B, Stack R, and the TAMI Study Group. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation 1990;82:781-791.
4. 4. Vogt A, von Essen R, Tebbe U, Feuerer W, Appel K-F, Neuhaus K-L. Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: retrospective analysis of 4 German multicenter studies. J Am Coll Cardiol 1993;21:1391-1395.
5. 5. Benhorin J, Moss AJ, Oakes D. Prognostic significance of nonfatal myocardial infarction. J Am Coll Cardiol 1990;15:253-258.
6. 6. Rutherford JD, Pfeffer MA, Moye LA, Davis BR, Flaker GC, Kowey PR, Lamas GA, Miller HS, Packer M, Rouleau JL, Braunwald E, on behalf of the SAVE Investigators. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. Circulation 1994;90:1731-1738.
7. 7. Mueller HS, Forman SA, Manegus MA, Chen LS, Knatterud GL, Braunwald E, for the TIMI Investigators. Prognostic significance of nonfatal reinfarction during 3-year follow-up: results of the Thrombolysis in Myocardial Infarction (TIMI) phase II clinical trial. J Am Coll Cardiol 1995;26:900-907.
8. 8. The Israeli Sprint Group. Secondary Prevention Reinfarction Israeli Nifedipine Trial: a randomized interventional trial of nifedipine in patients with acute myocardial infarction. Eur Heart J 1988;9:354-364.
9. 9. Maynard C, Weaver WD, Litwin PE, Martin JS, Kudenchuk PJ, Dewhurst TA, Eisenberg MS, Hallstrom AP, Chambers J, for the MITI Project Investigators. Hospital mortality in acute myocardial infarction in the era of reperfusion therapy (the Myocardial Infarction Triage and Intervention Project). Am J Cardiol 1993; 72:877-882.
10. 10. Multicenter Postinfarction Research Group. Risk stratification and survival after myocardial infarction. N Engl J Med 1983;309:331-336.
11. 11. Zaret BL, Wackers FJT, Terrin ML, Forman SA, Williams DO, Knatterud GL, Braunwald E, for the TIMI Study Group. Value of radionuclide rest and exercise left ventricular ejection fraction in assessing survival of patients after thrombolytic therapy for acute myocardial infarction: results of Thrombolysis in Myocardial Infarction (TIMI) Phase II study. JAm Coll Cardiol 1995;26:73-79.
12. 12. Dalen JE, Gore JM, Braunwald E, Borer J, Goldberg RJ, Passamani ER, Forman S, Knatterud G, and the TIMI Investigators. Six-and 12-month follow-up of the phase I Thrombolysis in Myocardial Infarction (TIMI) trial. Am J Cardiol 1988;62:179-185.
13. 13. Cannon CP, McCabe CH, Diver DJ, Herson S, Greene RM, Shah PK, Sequeira RF, Leya F, Kirshenbaum JM, Magorien RD, Palmeri ST, Davis V, Gibson CM, Poole WK, Braunwald E, and the TIMI 4 Investigators. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreptlase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 Trial. J Am Coll Cardiol 1994;24:1602-1610.
14. 14. Cannon CP, McCabe CH, Henry TD, Schweiger MJ, Gibson RS, Mueller HS, Becker RC, Kleiman NS, Haugland M, Anderson JL, Sharaf BL, Edwards SJ, Rogers WJ, Williams DO, Braunwald E, for the TIMI 5 Investigators. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 Trial. J Am Coll Cardiol 1994;23:993-1003.
15. 15. The GUSTO Angiographic Investigators. The comparative effects of tissue plasminogen activator, streptokinase, or both on coronary patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329: 1615-1622.
16. 16. Cannon CP, Braunwald E. GUSTO, TIMI, and the case for rapid reperfusion. Acta Cardiol 1994;49:1-8.
17. 17. Lamas GA, Flaker GC, Mitchell G, Smith SC Jr, Gersh BJ, Wun C-C, Moye L, Rouleau JL, Rutherford JD, Pfeffer MA, Braunwald E, for the Survival and Ventricular Enlargement Investigators. Effect of infarct related patency on prognosis after acute myocardial infarction. Circulation 1995;92:1101-1109.
18. 18. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996;125:605-613.
19. 19. Wackers FJT, Gibbons RJ, Verani MS, Kayden DS, Pellikka PA, Behrenbeck T, Mahmarian JJ, Zaret BL. Serial quantitative planar technetium-99m isonitrile imaging in acute myocardial infarction: efficacy for noninvasive assessment of thrombolytic therapy. J Am Coll Cardiol 1989;14:861-873.
20. 20. Antman EM, for the TIMI 9B Investigators. Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation 1996;94:911-921.
21. 21. Braunwald E, Cannon CP. Predictive survival markers as surrogate end points in thrombolytic trials of acute myocardial infarction. In: Califf RM, ed. Thrombolytic Therapy: New Standards of Care (Part III: Efficacy and Safety Issues). Belle Mead, NJ: Cahners Healthcare Communications; in press.
22. 22. The GUSTO Investigators. An international randomized trial comparing 4 thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329: 673-682.
23. 23. Ellis SG, Topol EJ, George BS, Kereiakes DJ, Debowey D, Sigmon KN, Pickel A, Lee KL, Califf RM. Recurrent ischemia without warning. Analysis of risk factors for in-hospital events following successful thrombolysis with intravenous tissue plasminogen activator. Circulation 1989;80:1159-1165.
24. 24. Muller JE, Rude RE, Braunwald E, Hartwell TD, Roberts R, Sobel BE, Ritter C, Parker CB, Jaffe AS, Stone PH, Raabe DS Jr, Willerson JT, Robertson T, and the MILIS Study Group. Myocardial infarct extension: occurrence, outcome, and risk factors in the Multicenter Investigation of Limitation of Infarct Size. Ann Intern Med 1988;108:1-6.
25. 25. Bauters C, Khanoyan P, McFadden EP, Quandalle P, Lablanche J-M, Bertrand ME. Restenosis after delayed coronary angioplasty of the culprit vessel in patients with a recent myocardial infarction treated by thrombolysis. Circulation 1995;91:1410-1418.
26. 26. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. J Am Coll Cardiol 1997;29:1474-1482.
27. 27. Zabel M, Hohnloser SH, Koster W, Prinz M, Kasper W, Just H. Analysis of creatine kinase, CK-MB, myoglobin, and troponin T time-activity curves for early assessment of coronary artery reperfusion after intravenous thrombolysis. Circulation 1993;87:1542-1550.